ValuEngine upgraded shares of Heska (NASDAQ:HSKA) from a hold rating to a buy rating in a research report report published on Tuesday morning, ValuEngine reports.
HSKA has been the topic of a number of other reports. BidaskClub upgraded Heska from a sell rating to a hold rating in a research report on Wednesday, March 27th. Zacks Investment Research downgraded Heska from a buy rating to a strong sell rating in a research report on Tuesday, March 5th. Canaccord Genuity reiterated a buy rating and set a $95.00 target price on shares of Heska in a research report on Monday, July 1st. Finally, Guggenheim assumed coverage on Heska in a research report on Thursday, May 23rd. They set a neutral rating on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of Hold and an average price target of $103.25.
NASDAQ:HSKA opened at $81.18 on Tuesday. The firm has a market capitalization of $643.77 million, a price-to-earnings ratio of 65.92 and a beta of 0.96. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.45 and a current ratio of 2.66. The company has a 50 day moving average of $78.04. Heska has a 12-month low of $68.74 and a 12-month high of $114.50.
Heska (NASDAQ:HSKA) last announced its quarterly earnings data on Tuesday, May 7th. The medical research company reported $0.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.19. The firm had revenue of $29.51 million for the quarter, compared to analyst estimates of $35.21 million. Heska had a return on equity of 8.36% and a net margin of 3.63%. On average, analysts expect that Heska will post 0.03 earnings per share for the current fiscal year.
In related news, Director Scott Humphrey acquired 1,000 shares of Heska stock in a transaction dated Thursday, May 30th. The shares were acquired at an average cost of $73.79 per share, for a total transaction of $73,790.00. Following the completion of the transaction, the director now directly owns 3,062 shares of the company’s stock, valued at $225,944.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 14.00% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the company. Principal Financial Group Inc. lifted its position in shares of Heska by 3.3% in the fourth quarter. Principal Financial Group Inc. now owns 57,404 shares of the medical research company’s stock valued at $4,942,000 after acquiring an additional 1,807 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Heska by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 219,430 shares of the medical research company’s stock valued at $18,893,000 after acquiring an additional 1,253 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its position in shares of Heska by 321.0% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 2,143 shares of the medical research company’s stock valued at $185,000 after acquiring an additional 1,634 shares in the last quarter. California Public Employees Retirement System lifted its position in shares of Heska by 19.0% in the fourth quarter. California Public Employees Retirement System now owns 8,642 shares of the medical research company’s stock valued at $744,000 after acquiring an additional 1,381 shares in the last quarter. Finally, Martingale Asset Management L P purchased a new stake in shares of Heska in the fourth quarter valued at $1,155,000. Institutional investors and hedge funds own 88.96% of the company’s stock.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
See Also: Do investors pay a separate front-end load every time they buy additional shares?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.